S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:CMRX

Chimerix (CMRX) Stock Price, News & Analysis

$1.06
+0.05 (+4.95%)
(As of 03/28/2024 ET)
Today's Range
$1.01
$1.09
50-Day Range
$0.91
$1.26
52-Week Range
$0.88
$1.57
Volume
370,388 shs
Average Volume
424,741 shs
Market Capitalization
$94.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

Chimerix MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
654.7% Upside
$8.00 Price Target
Short Interest
Healthy
1.59% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.49
Upright™ Environmental Score
News Sentiment
0.94mentions of Chimerix in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$6,598 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.77) to ($0.95) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.52 out of 5 stars

Medical Sector

205th out of 938 stocks

Pharmaceutical Preparations Industry

82nd out of 423 stocks

CMRX stock logo

About Chimerix Stock (NASDAQ:CMRX)

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 2 clinical trial for treating tumors, which harbor the H3 K27M mutation in glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2 (COVID-19) infection. The company has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

CMRX Stock Price History

CMRX Stock News Headlines

CMRX Apr 2024 2.000 call
Grab Your Free Bitcoin Today!
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
CMRX Apr 2024 1.000 put
Crypto Market Preps For Trillions Worth of Inflows!
Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.
Preview: Chimerix's Earnings
Chimerix Appoints Lisa Decker to Board of Directors
Positive Signs As Multiple Insiders Buy Chimerix Stock
Chimerix Appoints Michelle LaSpaluto As CFO
See More Headlines
Receive CMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chimerix and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/29/2024
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CMRX
Employees
72
Year Founded
2000

Price Target and Rating

Average Stock Price Target
$8.00
High Stock Price Target
$11.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+654.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-82,100,000.00
Net Margins
-25,337.96%
Pretax Margin
-25,337.96%

Debt

Sales & Book Value

Annual Sales
$320,000.00
Book Value
$2.17 per share

Miscellaneous

Free Float
80,289,000
Market Cap
$94.56 million
Optionable
Optionable
Beta
1.16

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Michael T. Andriole M.B.A. (Age 51)
    CEO, President & Director
    Comp: $592.95k
  • Dr. Allen S. Melemed M.B.A. (Age 60)
    M.D., Chief Medical Officer
    Comp: $605.29k
  • Ms. Michelle LaSpaluto (Age 49)
    Chief Financial Officer
  • Mr. Thomas J. Riga (Age 48)
    Chief Operating & Commercial Officer
  • Dr. Joshua E. Allen Ph.D.
    Chief Technology Officer
  • Dr. Michael A. Alrutz J.D. (Age 54)
    Ph.D., Senior VP, General Counsel & Corporate Secretary
    Comp: $619.5k
  • Dr. Roy W. Ware MBA
    Ph.D., Chief Manufacturing Technology Officer
  • Dr. Pablo Lee M.D.
    Head of Medical Affairs

CMRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Chimerix stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CMRX shares.
View CMRX analyst ratings
or view top-rated stocks.

What is Chimerix's stock price target for 2024?

3 brokers have issued 12 month target prices for Chimerix's shares. Their CMRX share price targets range from $6.00 to $11.00. On average, they predict the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 654.7% from the stock's current price.
View analysts price targets for CMRX
or view top-rated stocks among Wall Street analysts.

How have CMRX shares performed in 2024?

Chimerix's stock was trading at $0.9625 at the beginning of 2024. Since then, CMRX shares have increased by 10.1% and is now trading at $1.06.
View the best growth stocks for 2024 here
.

When is Chimerix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our CMRX earnings forecast
.

How were Chimerix's earnings last quarter?

Chimerix, Inc. (NASDAQ:CMRX) announced its earnings results on Thursday, February, 29th. The biopharmaceutical company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.03. Chimerix had a negative trailing twelve-month return on equity of 37.93% and a negative net margin of 25,337.96%.

What other stocks do shareholders of Chimerix own?
Who are Chimerix's major shareholders?

Chimerix's stock is owned by a variety of retail and institutional investors. Top institutional investors include Armistice Capital LLC (2.92%), Vestal Point Capital LP (1.57%), Goldman Sachs Group Inc. (1.33%), Goldman Sachs Group Inc. (1.33%), Bridgeway Capital Management LLC (1.16%) and Barclays PLC (1.00%). Insiders that own company stock include David Jakeman, Fred A Middleton, Martha J Demski, Michael T Andriole, Michelle Laspaluto and Robert J Meyer.
View institutional ownership trends
.

How do I buy shares of Chimerix?

Shares of CMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CMRX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners